scholarly journals Primary prevention of cardiovascular disease: Updated review of contemporary guidance and literature

2020 ◽  
Vol 9 ◽  
pp. 204800402094932
Author(s):  
Jack Stewart ◽  
Katherine Addy ◽  
Sarah Campbell ◽  
Peter Wilkinson
Keyword(s):  
Cardiovascular Disease ◽  
Primary Prevention ◽  
Healthcare Providers ◽  
Lipid Lowering ◽  
Treatment Modalities ◽  
Ageing Population ◽  
Mortality And Morbidity ◽  
Important Target ◽  
Previous Iteration ◽  
Prevention Of Cardiovascular Disease

Cardiovascular disease remains a substantial concern in terms of global mortality and morbidity, while prevalence of cardiovascular disease is increasing as treatment modalities improve survival. With an ageing population and increasing costs of chronic medical care, primary prevention of cardiovascular disease is an important target for healthcare providers. Since the previous iteration of this paper, new international guidelines have been produced regarding hypertension and lipid lowering therapies, whilst there is a growing body of evidence and new therapies emerging in other areas of lifestyle and pharmacotherapeutic intervention. This review outlines emerging evidence in the field and compares and contrasts contemporary recommendations from European and American guidelines.

scholarly journals New Male Users of Lipid-Lowering Drugs for Primary Prevention of Cardiovascular Disease: The Impact of Treatment Persistence on Morbimortality. A Longitudinal Study

2020 ◽  
Vol 17 (20) ◽  
pp. 7653
Author(s):  
Isabel Aguilar-Palacio ◽  
María José Rabanaque ◽  
Lina Maldonado ◽  
Armando Chaure ◽  
José María Abad-Díez ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Primary Prevention ◽  
Smoking Status ◽  
Lipid Lowering ◽  
Major Adverse Cardiovascular Events ◽  
Treatment Persistence ◽  
Effect Of Treatment ◽  
Lowering Drug ◽  
The Impact ◽  
Prevention Of Cardiovascular Disease

The objective of this study was to analyse persistence to lipid-lowering drug use for primary prevention of cardiovascular disease (CVD) in a new users cohort, to explore all-cause and cardiovascular related morbidity, comorbidity and mortality in this group and, finally, to study the relationship between persistence and morbimortality. We selected subjects who started lipid-lowering treatment for primary prevention of CVD between 1 January 2010 and 31 December 2017 (N = 1424), and classified them as treatment-persistent or -nonpersistent. Bivariate analyses were performed to compare sociodemographic and clinical variables, morbimortality and time to event between groups. The association between morbidities was explored using comorbidity network analysis. The effect of persistence was analysed using logistic regression and Cox survival analyses. Only 38.7% of users were persistent with treatment. Persistent and nonpersistent users had similar sociodemographic and clinical profiles, although differed in age, smoking status, and glycemia. Comorbidity networks revealed that the number of co-occurring diagnoses was higher in nonpersistent than persistent users. Adjusted analyses indicated a protective effect of treatment persistence, especially against major adverse cardiovascular events (MACE), but this effect was not statistically significant. Observational studies are crucial to characterize real-world effectiveness.

Therapie der Hypercholesterinämie in der Primärprävention

2019 ◽  
Vol 144 (05) ◽  
pp. 322-328 ◽  
Author(s):  
Veronika Sanin ◽  
Wolfgang Koenig
Keyword(s):  
Cardiovascular Disease ◽  
Primary Prevention ◽  
Density Lipoprotein ◽  
Reasonable Doubt ◽  
Lipid Lowering ◽  
Current Evidence ◽  
Individual Risk ◽  
Atherosclerotic Cardiovascular Disease ◽  
Mortality And Morbidity ◽  
Target Values

AbstractAtherosclerotic cardiovascular disease is the leading cause of premature mortality and morbidity worldwide. Dyslipidemia is a commonly encountered clinical condition and is an important determinant of cardiovascular disease. The causality of plasma low-density lipoprotein-cholesterol (LDL-C) in the pathophysiology of cardiovascular disease has been established beyond any reasonable doubt. In this context, individual risk estimation, the determination of target values and lipid-lowering strategies represent an essential part and a challenge in the daily clinical practice to prevent cardiovascular events. Statins are recommended as first-line therapy for patients with hypercholesterolemia in secondary prevention. Controversies remain in the context of primary prevention, however, as to which kind of subjects to treat, the magnitude of the benefit, and potential harm. This article gives a brief overview of the current evidence, guideline recommendations and strategies for lowering of LDL-C in the primary prevention of cardiovascular disease.

scholarly journals Landmark Lipid-Lowering Trials in the Primary Prevention of Cardiovascular Disease

2013 ◽  
Vol 36 (9) ◽  
pp. 516-523 ◽  
Author(s):  
Jonathan Chrispin ◽  
Seth S. Martin ◽  
Rani K. Hasan ◽  
Parag H. Joshi ◽  
C. Michael Minder ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Primary Prevention ◽  
Lipid Lowering ◽  
Prevention Of Cardiovascular Disease
Sign in / Sign up

Export Citation Format

Share Document